Keyphrases
Population-based Study
100%
Marginal Zone Lymphoma
100%
Clinical Characteristics
60%
Mini
40%
Overall Survival
40%
Mortality Risk
40%
Lymphoma Patients
40%
Relapse Risk
40%
Progression-free Survival
40%
Netherlands
20%
Radiotherapy
20%
Risk Reduction
20%
Diffuse Large B-cell Lymphoma (DLBCL)
20%
Poor Outcome
20%
Cancer Registry
20%
Cox Regression Analysis
20%
Immunochemotherapy
20%
Competing Risk Analysis
20%
Patient Counseling
20%
Elevated LDH
20%
Histological Transformation
20%
Biochemistry, Genetics and Molecular Biology
Overall Survival
100%
Progression Free Survival
100%
B Cell
50%
Cancer Registry
50%
Intravenous Immunoglobulin
50%
Lactate Dehydrogenase
50%
Medicine and Dentistry
MALT Lymphoma
100%
Overall Survival
40%
CHOP
40%
Progression Free Survival
40%
Radiation Therapy
20%
Immunoglobulin
20%
Diffuse Large B-Cell Lymphoma
20%
Cancer Registry
20%
Proportional Hazards Model
20%
Lactate Dehydrogenase
20%
Patient Counseling
20%
Risk Assessment
20%
Pharmacology, Toxicology and Pharmaceutical Science
Marginal Zone Lymphoma
100%
Overall Survival
40%
Progression Free Survival
40%
Chemotherapy
20%
Diffuse Large B Cell Lymphoma
20%
Cancer Registry
20%
Immunoglobulin
20%
Lactate Dehydrogenase
20%
Risk Assessment
20%
Immunology and Microbiology
Overall Survival
100%
Progression Free Survival
100%
B Cell
50%
Intravenous Immunoglobulin
50%